Source:http://linkedlifedata.com/resource/pubmed/id/12574145
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2003-2-7
|
pubmed:abstractText |
The matrix metalloproteinases (MMPs) are an endogenous family of proteolytic enzymes implicated to contribute to LV remodeling. However, broad-spectrum MMP inhibition (MMPi), particularly inhibition of interstitial collagenase (MMP-1), may not be clinically applicable. This study examined the effects of selective MMPi (sparing MMP-1) in a model of developing congestive heart failure. Pigs were randomly assigned to 3 groups: (1) rapid pacing for 3 weeks (240 bpm, n=10); (2) selective MMPi (20 mg/kg per day-PO;PGE7113313) and rapid pacing (n=12); and (3) controls (n=10). LV peak wall stress increased from controls with rapid pacing (140+/-6 versus 319+/-18 g/cm2; P<0.05) and was reduced with selective MMPi (208+/-9 g/cm2; P<0.05. Preload recruitable stroke work was reduced with rapid pacing (4.3+/-0.4 versus 1.2+/-0.2 dyne. cm/mm Hg; P<0.05) and was increased with selective MMPi (2.6+/-0.3 dyne. cm/mm Hg; P<0.05). Plasma norepinephrine increased by 6-fold in the rapid pacing group (P<0.05) and was reduced from untreated values with selective MMPi (P<0.05). At the myocardial level, myocyte cross-sectional area was increased with selective MMPi but fibrillar collagen volume fraction remained unchanged relative to control values. These results suggest that targeting a selective portfolio of myocardial MMP species for inhibition may provide a more rational therapeutic strategy in the setting of congestive heart failure.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Matrix Metalloproteinase 2,
http://linkedlifedata.com/resource/pubmed/chemical/Matrix Metalloproteinases,
http://linkedlifedata.com/resource/pubmed/chemical/Neurotransmitter Agents
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
1524-4571
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:day |
7
|
pubmed:volume |
92
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
177-85
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:12574145-Animals,
pubmed-meshheading:12574145-Cardiac Pacing, Artificial,
pubmed-meshheading:12574145-Diastole,
pubmed-meshheading:12574145-Disease Models, Animal,
pubmed-meshheading:12574145-Disease Progression,
pubmed-meshheading:12574145-Enzyme Inhibitors,
pubmed-meshheading:12574145-Heart Failure,
pubmed-meshheading:12574145-Hemodynamics,
pubmed-meshheading:12574145-Matrix Metalloproteinase 2,
pubmed-meshheading:12574145-Matrix Metalloproteinases,
pubmed-meshheading:12574145-Myocardium,
pubmed-meshheading:12574145-Neurotransmitter Agents,
pubmed-meshheading:12574145-Swine,
pubmed-meshheading:12574145-Systole,
pubmed-meshheading:12574145-Ventricular Function, Left
|
pubmed:year |
2003
|
pubmed:articleTitle |
Selective matrix metalloproteinase inhibition with developing heart failure: effects on left ventricular function and structure.
|
pubmed:affiliation |
Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston, SC 29425, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|